Pembrolizumab for Newly Diagnosed Glioblastoma

Sponsor
University of Zurich
Study ID
NCT03899857
Phase
PHASE2
Status
Active Not Recruiting

Conditions

  • Newly Diagnosed Glioblastoma

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Pembrolizumab — DRUG
    Pembrolizumab will be added to standard of care

Study Details

The study explores the addition of pembrolizumab to temozolomide-based radiotherapy in patients with newly diagnosed glioblastoma.

Key Dates

Start date
Oct 21, 2020
Status verified
May 2024
Primary completion
Apr 30, 2026
Completion
Dec 31, 2026

Study Design

Enrollment
56 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Pembrolizumab
    Temozolomide-based radiochemotherapy (TMZ/RT=\>TMZ) represents the standard of care for patients with newly diagnosed glioblastoma. In this study, pembrolizumab will be administered (200 mg every 3 weeks) in addition to TMZ/RT=\>TMZ.

Primary Outcome Measure

Overall survival at 12 months [ Time Frame: At 12 months ]

Related Studies